Generali Investments Towarzystwo Funduszy Inwestycyjnych Cuts Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Generali Investments Towarzystwo Funduszy Inwestycyjnych decreased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 45.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,300 shares of the biopharmaceutical company’s stock after selling 1,100 shares during the quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych’s holdings in Gilead Sciences were worth $120,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. AMF Tjanstepension AB increased its holdings in shares of Gilead Sciences by 14.7% in the 3rd quarter. AMF Tjanstepension AB now owns 400,819 shares of the biopharmaceutical company’s stock valued at $33,645,000 after acquiring an additional 51,390 shares during the last quarter. Swedbank AB increased its holdings in shares of Gilead Sciences by 10.2% in the 3rd quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock valued at $171,672,000 after acquiring an additional 189,622 shares during the last quarter. Pallas Capital Advisors LLC increased its holdings in shares of Gilead Sciences by 35.9% in the 3rd quarter. Pallas Capital Advisors LLC now owns 7,836 shares of the biopharmaceutical company’s stock valued at $696,000 after acquiring an additional 2,069 shares during the last quarter. Fidelis Capital Partners LLC increased its holdings in shares of Gilead Sciences by 6.3% in the 3rd quarter. Fidelis Capital Partners LLC now owns 4,494 shares of the biopharmaceutical company’s stock valued at $392,000 after acquiring an additional 268 shares during the last quarter. Finally, Lodestar Private Asset Management LLC purchased a new position in shares of Gilead Sciences in the 3rd quarter valued at about $230,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total transaction of $260,225.00. Following the completion of the transaction, the chief financial officer now owns 169,061 shares of the company’s stock, valued at approximately $17,597,559.49. This trade represents a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 293,356 shares of company stock valued at $29,166,240. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $111.99 on Friday. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $112.57. The company has a market capitalization of $139.57 billion, a P/E ratio of 302.68, a PEG ratio of 0.71 and a beta of 0.18. The business has a 50 day moving average price of $96.98 and a 200 day moving average price of $89.65. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a dividend of $0.79 per share. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. This represents a $3.16 annualized dividend and a yield of 2.82%. Gilead Sciences’s dividend payout ratio (DPR) is presently 854.05%.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of recent analyst reports. DZ Bank upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price objective on the stock in a report on Thursday, February 13th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, February 12th. Barclays upped their target price on Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research report on Thursday, November 7th. Piper Sandler upped their target price on Gilead Sciences from $105.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, February 12th. Finally, Maxim Group cut Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Friday, November 8th. Eleven research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have issued a strong buy rating to the stock. According to MarketBeat, Gilead Sciences has a consensus rating of “Moderate Buy” and a consensus price target of $102.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.